Show simple item record

dc.contributor.authorCapdevila, J
dc.contributor.authorFazio, N
dc.contributor.authorLopez-Lopez, C
dc.contributor.authorTeule, A
dc.contributor.authorValle, Juan W
dc.contributor.authorTafuto, S
dc.contributor.authorCustodio, AB
dc.contributor.authorReed, N
dc.contributor.authorRaderer, M
dc.contributor.authorGrande, E
dc.contributor.authorGarcia-Carbonero, R
dc.contributor.authorJimenez-Fonseca, P
dc.contributor.authorAlonso, V
dc.contributor.authorAntonuzzo, L
dc.contributor.authorSpallanzani, A
dc.contributor.authorBerruti, A
dc.contributor.authorSevilla, I
dc.contributor.authorMunoa, AL
dc.contributor.authorHernando, J
dc.contributor.authorIbrahim, T
dc.date.accessioned2019-11-19T16:01:09Z
dc.date.available2019-11-19T16:01:09Z
dc.date.issued2019en
dc.identifier.citationCapdevila J, Fazio N, L�pez-L�pez C, Teule A, Valle JW, Tafuto S, et al. Progression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): updated results from the phase II TALENT trial (GETNE 1509). J Clin Oncol. 2019;37(4_suppl):332-.en
dc.identifier.doi10.1200/JCO.2019.37.4_suppl.332en
dc.identifier.urihttp://hdl.handle.net/10541/622480
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/ 10.1200/JCO.2019.37.4_suppl.332en
dc.titleProgression-free survival (PFS) and subgroups analyses of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs): updated results from the phase II TALENT trial (GETNE 1509)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentMedical Oncology Department, Vall d�Hebron University Hospital; Vall d�Hebron Institute of Oncology (VHIO)., Barcelona, Spainen
dc.identifier.journalJournal of Clinical Oncologyen


This item appears in the following Collection(s)

Show simple item record